Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 10/20 | 0.60 |
| ▸ | IDO1 | P14902 | 16/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438248 | 0.82 | IDO1 (0.78) | AGXTIDO1CYP3A4 | |
| SCHEMBL1714959 | 0.80 | AGXT (0.65) | AGXTIDO1CYP3A4 | |
| SCHEMBL8750441 | 0.80 | LPL (0.48) | CYP3A4 | |
| SCHEMBL142480 | 0.79 | LPL (0.62) | CYP3A4 | |
| SCHEMBL14232112 | 0.78 | LPL (0.46) | CYP3A4 | |
| Hydroxyamine SCHEMBL17181093 | 0.76 | LPL (0.61) | CYP3A4 | |
| SCHEMBL8750358 | 0.76 | LPL (0.45) | CYP3A4 | |
| SCHEMBL21633649 | 0.76 | LPL (0.45) | CYP3A4 | |
| SCHEMBL26733845 | 0.76 | THRB (0.48) | AGXTIDO1 | |
| SCHEMBL9839848 | 0.76 | LPL (0.59) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | AGXT 2638/4885IDO1 4025/4885CYP3A4 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.